You are currently viewing Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in nepal (IVI-T003)

Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in nepal (IVI-T003)

Project Summary

Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial

Study Duration

9 months

Objectives

The co-primary endpoints were:

 (1) non-inferiority of immunogenicity of the Vi-DT vaccine (pooled groups A–C) versus the Vi-TT vaccine (group D) at 4 weeks after vaccination, measured by the anti-Vi IgG seroconversion rate, which was defined as the proportion of participants with a four-fold or greater increase in antibody titres compared with baseline; and

 (2) the lot-to-lot consistency of the Vi-DT vaccine, measured by immune equivalence of the anti-Vi IgG geometric mean titre (GMT) at 4 weeks after receipt of the three Vi-DT vaccine lots (lot 1 vs lot 2, lot 1 vs lot 3, and lot 2 vs lot 3).

Implementation Site

Dhulikhel Hospital, Baluwa Health Center

Team Members

Principal Investigator(s): Prof. Dr. Rajeev Shrestha, Dr. Dipesh Tamrakar

Co-Investigator(s): Dr. Amit Khadgi, Dr. Pranodan Poudel, Dr. Srijana Dongol Singh, Mr. Surendra Madhup, Dr. Anmol Purna Shrestha, Dr. Rajendra Tamrakar

Project Coordinator: Ms. Pragya Thapa, Dr. Amit Khadgi

Research Assistants: Ms. Anita Shrestha, Ms. Reena Kharbuja, Ms. Usha Acharya, Ms. Shanti Bogati, Ms. Sunita Shrestha, Ms. Sapana Khadka, Ms. Jyoti Palanchoke, Ms. Shreena Shrestha, Ms. Sunaina Shrestha

For more detailed Information, Please contact:  rajeev.shrestha@kusms.edu.np / rmaleku@hotmail.com or dipesht@kusms.edu.np